Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
Summary
- Relacorilant is a selective glucocorticoid receptor modulator in development for the treatment of endogenous hypercortisolism (Cushing syndrome) of all etiologies
- The presented ongoing open-label phase 2/3 extension study investigates the long-term safety and efficacy of relacorilant treatment in patients with endogenous CS
- This interim analysis provides support that relacorilant is well-tolerated with an acceptable risk/benefit profile in patients treated for up to 6 years
- Relacorilant led to improvement and/or long-term maintenance of clinical and cardiometabolic benefit